SOURCE-LINKED STUDY SUMMARY
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- SURPASS-3 compared once-weekly tirzepatide with daily, treat-to-target insulin degludec.
- Who / model studied
- The analysis included 1437 insulin-naive adults with type 2 diabetes inadequately controlled by metformin, with or without an SGLT2 inhibitor.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- At week 52, tirzepatide reduced body weight by 7·5 kg to 12·9 kg, while insulin degludec increased it by 2·3 kg.
- Limitations & context
- The trial was open-label. Treatment discontinuation because of adverse events was more common with tirzepatide, and methodological quality was not formally appraised here.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(21)01443-4